Hormone Replacement Therapies and Other Hormone Therapies: Global Markets
- The global market for HRT will increase from $14.7 billion in 2007 to an estimated $15.8 billion by the end of 2008. It should reach $25.9 billion in 2013, a compound annual growth rate (CAGR) of 10.4%.
- Antiestrogens, SERMs, antiandrogens, aromatase inhibitors and LH RH agonists have the largest share of the market, worth $7.5 billion in 2007. This is expected to increase to $8.3 billion in 2008 and $13.7 billion in 2013, for a CAGR of 10.7%.
- Recombinant growth, thyroid and testosterone hormone therapies have the second largest market share, generating $4.1 billion in 2007 and an estimated $4.4 billion in 2008. This should increase at a CAGR of 9.9% to reach $7.0 billion in 2013.